Login to Your Account



Genentech, Constellation Sign $95M Epigenetic Deal

By Catherine Shaffer
BioWorld Today Contributing Writer

Tuesday, January 17, 2012

The science of epigenetics will get a $95 million boost from a new collaboration between Constellation Pharmaceuticals Inc. and Roche Group. The two companies will launch a sweeping three-year collaboration to seek new treatments for cancer and other diseases based on epigenetics and chromatin biology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription